Role of Ulinastatin in Preventing Severe Sepsis and Consequent Morbidities and Mortality

• Status: Recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will enhance the theory in the frame of reference on the efficacy of Ulinastatin while managing sepsis and subsequent morbidity and mortality. Moreover, the present study will explore Ulinastatin's prophylactic role in progression of multiple organ dysfunctions. Furthermore, the study will have the clinical implications in predicting the ICU admitted patient's stay and related cost in the context of new drug. Current researches will explore the new dimensions in Pakistan's healthcare facilities, paving the way of future academics to analyze it in order to enhance healthcare outcomes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jinnah Postgraduate Medical Centre
• Treatments: Urinastatin

Criteria

Inclusion Criteria:

• Age >18 or <60

• Sepsis, and severe sepsis, as defined in operational definitions

• Patients voluntarily agreed to participate in the study after informed consent

Exclusion Criteria:

• Fulminant hepatic failure

• Acute cerebrovascular accidents

• Acute poisoning

• Chronic Kidney Disease stage 5

• Diagnosed case of immune thrombocytopenia

• Low output cardiac failure, with left ventricular ejection fraction <20%

• Advance chronic obstructive pulmonary disease on long term oxygen therapy

• Lactation or pregnancy